PRESS RELEASE published on 04/07/2026 at 18:59, 5 months 9 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 5 months 21 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 5 months 21 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 5 months 25 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 5 months 30 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
PRESS RELEASE published on 03/18/2026 at 10:15, 5 months 30 days ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 6 months 7 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 6 months 7 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 6 months 8 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 6 months 8 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
Published on 09/17/2026 at 13:00, 24 minutes ago Organto Foods Strengthens Scalable European Operating Platform and Launches AI Powered Operational Transformation
Published on 09/17/2026 at 13:00, 24 minutes ago Gold Terra Announces Fall Drilling with Three (3) Rigs Active on the Con Mine, Yellowknife, NWT
Published on 09/17/2026 at 13:00, 24 minutes ago NiobiumX Mining Inc. Appoints Athabasca Basin Discovery Geologist Erik Sehn to Board of Directors
Published on 09/17/2026 at 12:00, 1 hour 24 minutes ago Banyan Gold Intersects 1.05 g/t Gold over 52.8 metres and Bonanza-Grade Gold at Powerline Deposit, AurMac, Yukon, Canada
Published on 09/17/2026 at 10:00, 3 hours 24 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/17/2026 at 13:05, 19 minutes ago Aurzen Expands Its Presence in Germany with Launch on Joybuy, Bringing EAZZE D1 and ZIP to More Consumers
Published on 09/17/2026 at 13:00, 24 minutes ago Original-Research: Smartbroker Holding AG (von GBC AG): BUY
Published on 09/17/2026 at 13:00, 24 minutes ago Medartis Group acquires M.A.R.C. Institute to establish its first surgical education center in the US
Published on 09/17/2026 at 13:00, 24 minutes ago Ascory Bank AG enters into a strategic, long-term partnership with Mount Street to deliver outsourced credit administration and surveillance
Published on 09/16/2026 at 17:45, 19 hours 39 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 6 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 19 hours ago Report on the Combined General Meeting of the 10th of September 2026
